**Isaac George, MD**
**Surgeon**
Columbia University Medical Center

**Printed as of 10/13/2026**

# Disclosures

## Personal Commercial (10)

| Company Name | Relationship Category | Compensation Level | *Topic Area(s)* |
|---|---|---|---|
| ***Self*** | | | |
| Atricure | Consultant Fees/Honoraria | Significant (>= $5,000) | *Arrhythmias and Clinical EP* |
| BCI | Consultant Fees/Honoraria | Significant (>= $5,000) | *Other* |
| boston scientific | Consultant Fees/Honoraria | Significant (>= $5,000) | *Invasive CV Angio and Interventions* |
| Cardiomech | Consultant Fees/Honoraria | Modest (< $5,000) | *Valvular Heart Disease* |
| Durvena | Consultant Fees/Honoraria | None ($0) | *Cardiothoracic Surgery* |
| Encompass Medical | Consultant Fees/Honoraria | Significant (>= $5,000) | *Invasive CV Angio and Interventions* |
| Foldax | Consultant Fees/Honoraria | Modest (< $5,000) | *Cardiothoracic Surgery* |
| medtronic | Consultant Fees/Honoraria | Modest (< $5,000) | *Invasive CV Angio and Interventions* |
| Valcare Medical | Consultant Fees/Honoraria | Modest (< $5,000) | *Valvular Heart Disease* |
| Vdyne | Consultant Fees/Honoraria | Modest (< $5,000) | *Valvular Heart Disease* |

## Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

## Personal Organizational or Other Non-Commercial (0)

No disclosures on record

## Clinical Trial Enroller (4)

| Trial Name | Trial Sponsor | Trial Funding Source |
|---|---|---|
| Acurate Low Risk | Boston Scientific | Boston Scientific |
| Alliance | Edwards | Edwards |
| Pascal | Edwards | |
| Apollo | MEDTRONIC | |

## Institutional Financial Decision-Making Role (0)

No disclosures on record

## Expert Witness Testimony (3)

| Year | Case Title | Represented | Description | Compensation |
|---|---|---|---|---|
| ***Self*** | | | | |
| 2020 | Heart failure | Defendant | pt with HF who did poorly | Significant (>= $5,000) |
| 2020 | CABG and leg injury | Defendant | CABG with vascular injury | Significant (>= $5,000) |
| 2019 | TAVR stroke | Defendant<br>*† none* | TAVR patient with stroke | Modest (< $5,000) |

*† Commercial Funding Source | ‡ Trial Name*

# Agreement

## Certified Education Attestation | Signed on 2/3/2026

*URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement*

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 2/3/2026
*URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement*

**Embargo** | Signed on 2/3/2026
*URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement*

**On-Going Obligation Agreement** | Signed on 2/3/2026

---

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.